Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:2/19/2009

h 31, 2008, June 30, 2008, and September 30, 2008.

                            ISTA Pharmaceuticals, Inc.
                       Consolidated Statements of Operations
                       (in thousands, except per share data)
                                    (unaudited)

                                   Three Months Ended       Year Ended
                                      December 31,          December 31,
                                    2008       2007        2008      2007
    Revenue:
        Product sales, net      $  28,049  $  19,092   $  82,798  $  58,589
        License revenue                70         70         278        278
    Total revenue                  28,119     19,162      83,076     58,867

    Cost of products sold           7,186      5,447      21,947     15,864
    Gross profit margin            20,933     13,715      61,129     43,003
    Costs and expenses:
        Research and development    7,347     11,572      32,400     32,492
        Selling, general, and
          administrative           13,389     11,503      53,539     46,603
    Total costs and expenses       20,736     23,075      85,939     79,095

    Gain / (Loss) from operations     197     (9,360)    (24,810)   (36,092)
    Interest income                    35        655         714      2,141
    Interest expense               (2,119)    (1,151)     (6,578)    (4,270)

    Net loss                    $  (1,887) $  (9,856)  $ (30,674) $ (38,221)

    Net loss per common share,
      basic and diluted         $   (0.06) $   (0.30)  $   (0.93) $   (1.29)
    Shares used in computing
      net loss per common share,
       basic and diluted           33,056     32,884      33,028     29,621



                            ISTA Pharmaceuticals, Inc.
                    Summary of Consolidated Balance Sheets Data
                                  (in thousands)
                                  
'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) pending in the U.S. District ... litigation’s next Case Management Conference for April 21st ... meeting will address the progress of product liability ... experienced heart attacks, strokes and other cardiovascular complications ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
(Date:3/29/2015)... Ore. (PRWEB) March 29, 2015 Youth ... Marion counties in Oregon to assess the feasibility of ... with emotional and behavioral problems and their families. , ... to select participants that will be provided technical assistance ... Oregon counties join six other national awardees chosen by ...
(Date:3/29/2015)... 29, 2015 Final Cut Pro ... from Pixel Film Studios, entitled TranSports. , “TranSports ... for Final Cut Pro X,” said Christiana Austin, CEO ... tools needed to effortlessly transition using this cool sports ... new and uniquely styled transition pack for Final Cut ...
(Date:3/29/2015)... TN (PRWEB) March 29, 2015 North ... several PT Online Continuing Education Courses . ... 10.0 hours of CME - TPTA, approval # 56399TX ... the evaluation of the shoulder complex - 10.5 hours ... Approved #56400TX , Examination and Treatment of the SI ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2
... Findings of a recent study suggests hunger may be ... researchers // studied 16 men who agreed to skip breakfast. ... evening. Participants were asked to consume sugary, salty or bitter ... not swallow the drinks, but instead spit them out after ...
... with chemo-resistant leukemia, a new drug is showing promising ... experimenting with bacteria-based recombinant immunotoxins. An immunotoxin is bioengineered ... part of the antibodies that are commonly used to ... encouraging results in a phase II study. ,Researchers ...
... Latest research shows the chickenpox vaccine loses some ... vaccination.// Parents are encouraged to vaccinate their children ... Consequently, researchers were prompted to further investigate the ... individuals. ,Researchers studied nearly 350 children ...
... common form of cancer in the United States. According to ... against colon cancer. In addition, soy protein may help minimize ... fed five different diets to female mice and followed their ... the effects of specific ingredients. Diet one contained milk protein, ...
... get up and get moving. Breast cancer survivors ... body esteem and better mood than sedentary breast ... ,Researchers compared 40 women who said they regularly ... cancer survivors. Regular exercisers reported significantly more positive ...
... depression may have an increased risk of heart disease ... than 93,600 older women who participated in the Women's ... long-term program designed to determine how biological and lifestyle ... and other health conditions. For this study, participants were ...
Cached Medicine News:
(Date:3/29/2015)...  Three-month paliperidone palmitate, an investigational atypical antipsychotic, ... in patients with schizophrenia, according to a new ... the Journal of the American Medical ... of the study served as the basis for ... three-month paliperidone palmitate injection to treat schizophrenia in ...
(Date:3/27/2015)... 27, 2015 BioCorRx, Inc. ( ... California is a healthcare solutions organization, which focuses ... at $22 billion in the U.S. alone. The Company created ... Naltrexone in a specially compounded form for outpatient surgical implantation. ... and New Zealand ) to the ...
(Date:3/27/2015)... 2015 Across the global healthcare landscape, the ... clinical development, market education, and regulatory compliance. As emerging ... function is expected to increase in prominence and follow ... According to research by benchmarking firm, Best Practices, LLC, ... to Medical Affairs. Among companies in India ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... Aug. 16 Endologix, Inc. (Nasdaq: ELGX ... announced today that it has entered into a development ... for its balloon expandable stent technology. Evasc is a ... patented stent is made from cobalt chromium and is ...
... PRA International, a leading Clinical Research Organization, will host ... drug development on 24 August 2010 at 11:30 am ... PRA,s Scientific Affairs unit, will be the presenter. ... of the expensive failures that pharmaceutical companies experience during ...
Cached Medicine Technology:Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology 2Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology 3PRA International Hosts Audio Conference on CV Drug Development 2
Blood sedimentation rate analysis...
Blood sedimentation rate analysis...
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
Medicine Products: